NEUN Neurogenesis Inc (CE)

"beCALM'd" Has Been Available in Market for 22 Years With No Claims and No Serious Side-Effects NeuroGenesis, Inc., (OTC PK: NEUN) is pleased to announce their patented nutritional supplement known as "beCALM'd" is experiencing a continued month over month increase in sales. This comes at a time when the FDA has repeatedly taken commonly used and known drugs sold by major pharmaceuticals off the market or listed them as "dangerous". NeuroGenesis has been selling their nutritional supplement known as "beCALM'd" for over 22 years with no claims and no significant side-effects. This product was designed specifically to treat Attention Deficit/Hyperactivity Disorders (ADHD). According to (neurologist Dr. Fred) Baughman, "500,000 children in the United States were diagnosed with ADHD in 1985 and between 5 and 7 million have been diagnosed today." NeuroGenesis has determined the steady month over month increase in sales of "BeCALM'd" has been attributed to four factors: 1.) Continued Global Rise of Individuals Diagnosed with ADHD 2.) FDA Aggressively Taking Commonly Used and Known Drugs Off Market or Listing them as "Dangerous" 3.) BeCALM's 22 Year Record of No Claims and No Significant Side-Effects. 4.) Increase in Individuals Switching from ADHD Drugs to Nutritional Supplement Known as BeCalm'd. Heading into the second half of 2006, NeuroGenesis will begin aggressively marketing BeCALM in order establish the product as a brand name and a safer alternative to treat ADHD. Currently over 91 million individuals within the United States are taking nutritional and herbal supplements to safely improve their health. For more information, please visit the website at www.neurogenesis.com or call (281) 557-7877 ext. 101. Disclaimer: This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of l995 relating to aspects of the Company's operations and strategies. Important factors could occur to cause actual results to differ materially from those described herein. There is a risk that the Company may incur losses. Readers are urged to consider these cautionary statements carefully. Forward-looking statements speak only as of the date of this news release, and the Company disclaims any obligations to update such statements.